

HORIBA acquires MedTest Holdings to expand laboratory chemistry offerings

04 February 2021 | News

The acquisition will combine the complimentary innovative technology offerings of the HORIBA Medical segment with MedTest Dx technology, Clinitox, and Pointe Scientific's R&D and manufacturing capabilities

Japan based HORIBA has announced that it has acquired MedTest Holdings, Inc. The acquisition will combine the complimentary innovative technology offerings of the HORIBA Medical segment with MedTest Dx technology, Clinitox, and Pointe Scientific's R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD testing customers.

"Our long term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative chemistry and immunochemistry technology solutions. I am extremely pleased that this long term vision has resulted in acquiring MedTest," said Atsushi Horiba, Chairman & Group CEO HORIBA Ltd.

"This acquisition provides HORIBA Medical the opportunity to address the IVD market's multidisciplinary requirements along with the complimentary innovative technology of Pointe Scientific and MedTest's high quality chemistry solutions. HORIBA Medical will continue offering innovative technology solutions through its Yumizen brand and current distribution channels," said HORIBA Medical segment leader Dr Jai Hakhu, Chairman and CEO of HORIBA Instruments Incorporated and President of HORIBA ABX SAS in France.

HORIBA Medical will continue investing in innovative technologies for future IVD requirements.